5CV — CureVac NV Income Statement
0.000.00%
Last trade - 00:00- €612.31m
- €186.82m
- €67.42m
Annual income statement for CureVac NV, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 20-F | 20-F | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 12.9 | 17.4 | 48.9 | 103 | 67.4 |
| Cost of Revenue | |||||
| Gross Profit | -4.87 | -10.6 | 34.7 | -135 | -91.6 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 85.7 | 117 | 159 | 515 | 317 |
| Operating Profit | -72.8 | -99.5 | -110 | -412 | -249 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -71.1 | -100 | -130 | -412 | -249 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -71.2 | -99.9 | -129 | -412 | -249 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -71.2 | -99.9 | -129 | -412 | -249 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -71.2 | -99.9 | -129 | -412 | -249 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.404 | -0.566 | -0.716 | -2.35 | -1.17 |
| Dividends per Share |